Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PLC Systems

This article was originally published in The Gray Sheet

Executive Summary

Company's Heart Laser transmyocardial revascularization system shows "significant promise" as an alternative therapy for angina patients who are not able to undergo angioplasty or cardiopulmonary bypass surgery, according to results of two Phase II studies presented Nov. 17 at the American Heart Association annual meeting in Dallas. After an accumulated 70 patient months, a Harvard Medical School study showed that: eight patients reduced their angina class ratings by one to four classes; blood flow in the treated area improved; fixed defects were reduced in size by 40%; and there was an average 25% reduction in the size of reversible defects by six months. In a Texas Heart Institute study, 78% of treated areas showed a mean blood flow increase of 9% at three months, and stress-induced perfusion defects dropped 7%
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT003109

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel